Three patient deaths during Novartis's clinical trials of CAR-T cell therapy for autoimmune and neurological diseases have prompted the company to halt its programs, with Bristol Myers Squibb following suit in a precautionary pause of its own related studies. The moment asks a question medicine has faced before: whether a tool forged in one crucible of suffering can be safely carried into another. What proved transformative in blood cancer treatment may carry risks that are not yet understood when turned toward the more delicate task of quieting an immune system that has turned against itself.
Novartis halts CAR-T trials after three deaths; Bristol Myers also pauses studies
Three patient deaths occurred during CAR-T cell therapy trials conducted by Novartis.
Three deaths exposed a critical vulnerability in translating cancer therapy to autoimmune disease.
Mark
So three people died in Novartis trials. Do we know what actually killed them?
Mimi
Not yet. Novartis said the deaths were connected to the CAR-T therapy, but they haven't released the specific mechanisms. That's what the investigation is supposed to uncover.
Luke
Right—and that's important to flag. We know three people died and Novartis halted the trials, but the actual cause of death isn't public information yet. We're working from the company's determination that the therapy was involved, not from independent confirmation.
Mark
Why would CAR-T work for cancer but fail for autoimmune disease?
Mimi
In cancer, you're trying to kill tumor cells. In autoimmune disease, you're trying to dial down an overactive immune response. The engineering and dosing strategies that are safe for one goal might be dangerous for the other.
Luke
That's the theory, anyway. But we don't actually know yet whether the problem is specific to how Novartis designed their cells, or whether it's a fundamental issue with using CAR-T for autoimmune disease at all.
Mark
Bristol Myers paused too. Does that mean they think their program has the same problem?
Mimi
They said it was precautionary. They didn't specify which programs or whether they've seen any safety signals in their own trials.
Luke
Exactly. Bristol Myers pausing could mean they're genuinely concerned about a class-wide issue, or it could mean they're being cautious until more information comes out. We don't know which.
Mark
What happens to the patients in these trials now?
Mimi
They're out. The trials are halted. Novartis and Bristol Myers will need to investigate before they can restart anything.
Luke
And we don't know how many patients were enrolled or what their status is now—whether they're being monitored for delayed effects, what support they're receiving. That's another gap in what's been disclosed.
Il Polso
- Three patients died during Novartis's CAR-T trials for autoimmune and neurological diseases, triggering an immediate and sweeping halt across the company's cell therapy programs.
- Bristol Myers Squibb moved in parallel to pause its own CAR-T studies, signaling that the industry is treating the deaths as a shared safety signal rather than an isolated incident.
- Neither company has disclosed the specific mechanisms behind the fatalities, leaving investigators, regulators, and enrolled patients in a state of urgent uncertainty.
- The FDA and internal teams will now undertake detailed forensic review — autopsies, cell analysis, patient histories — to determine whether the risk is design-specific or fundamental to the approach.
- Dozens of companies developing CAR-T therapies beyond oncology now face heightened scrutiny, and development timelines across the sector may slow considerably as the field waits for answers.
Three patient deaths during Novartis's clinical trials of CAR-T cell therapy for autoimmune and neurological diseases have prompted the company to halt its programs, with Bristol Myers Squibb following suit in a precautionary pause of its own related studies. The moment asks a question medicine has faced before: whether a tool forged in one crucible of suffering can be safely carried into another. What proved transformative in blood cancer treatment may carry risks that are not yet understood when turned toward the more delicate task of quieting an immune system that has turned against itself.
Novartis has halted its clinical trials of CAR-T cell therapies for autoimmune and neurological diseases after three patients died during the studies. Investigators determined the deaths were connected to the experimental treatment, prompting the company to pause all related programs pending a thorough investigation.
CAR-T therapy works by extracting a patient's immune cells, genetically engineering them to recognize specific targets, and reinfusing them into the body. The approach has become a standard treatment for certain blood cancers. When researchers extended the logic to autoimmune diseases — where the goal is to suppress a misdirected immune response rather than destroy malignant cells — the premise seemed sound. The three deaths revealed how much can go wrong in that translation.
Bristol Myers Squibb, which runs its own CAR-T pipeline, announced a parallel pause in response to the Novartis findings. The coordinated caution signals that the pharmaceutical industry is unwilling to advance similar programs without understanding what caused the fatalities. Both companies now face the difficult work of forensic investigation: autopsy findings, laboratory analysis of the engineered cells, and review of patient histories to identify what went wrong.
The setback illuminates a broader challenge in medical innovation. Therapies that succeed in one disease context do not automatically transfer safely to another, particularly when the therapeutic goal shifts from eliminating a discrete population of cells to modulating a complex, system-wide biological process. For the many companies developing engineered cell therapies beyond oncology, the Novartis deaths are a sobering signal — and the field will be watching closely to learn whether the risk lies in one company's particular design, or in the approach itself.
Novartis announced a halt to its clinical trials of CAR-T cell therapies designed to treat autoimmune and neurological diseases after three patients died during the studies. The company's decision to pause these programs came after investigators determined the deaths were connected to the experimental treatment approach. The move represents a significant setback for a class of therapies that has shown promise in cancer treatment but has faced mounting safety questions when applied to other disease areas.
CAR-T cell therapy works by extracting immune cells from a patient, genetically engineering them to recognize and attack disease targets, and then reinfusing the modified cells back into the body. The approach has become standard treatment for certain blood cancers, where the goal is to destroy malignant cells. When researchers began exploring whether the same mechanism could treat autoimmune conditions—where the immune system mistakenly attacks the body's own tissues—the logic seemed sound: reprogram immune cells to suppress rather than activate the harmful response. But the three deaths in Novartis's trials exposed a critical vulnerability in that translation.
The company did not immediately disclose detailed information about the circumstances surrounding each death or the specific mechanisms that led to the fatal outcomes. What became clear was that the safety profile of CAR-T therapy in autoimmune disease differed substantially from its established use in oncology. Novartis stated it was pausing both its immunology-focused CAR-T programs and its neurological applications of the technology pending a thorough investigation into what went wrong.
Bristol Myers Squibb, which has its own CAR-T development pipeline, announced it was also pausing related studies in response to the Novartis deaths. The decision signaled that the broader pharmaceutical industry was treating the safety signal seriously and was unwilling to continue advancing similar programs without understanding the root cause of the fatalities. Bristol Myers did not specify which of its CAR-T programs would be affected by the pause, but the company indicated the action was precautionary and reflected heightened vigilance across the sector.
The pauses create immediate uncertainty for patients enrolled in these trials and for the companies' development timelines. Novartis and Bristol Myers will need to conduct detailed investigations into the adverse events, potentially including autopsy findings, laboratory analysis of the engineered cells, and examination of patient medical histories to identify whether specific risk factors or treatment protocols contributed to the deaths. Regulators, including the FDA, will likely scrutinize the data and may require substantial additional safety work before trials can resume.
The setback underscores a broader challenge in translating cancer immunotherapies to other disease areas. What works in one context—where the goal is to eliminate a discrete population of malignant cells—does not automatically transfer to conditions where the therapeutic goal is more nuanced, such as selectively dampening an overactive immune response while preserving protective immunity. The deaths in Novartis's autoimmune CAR-T trials suggest that the engineering approaches and dosing strategies that proved safe in oncology may carry unacceptable risks when applied to patients with different underlying pathologies.
For the field of cell therapy more broadly, the pauses represent a cautionary moment. Dozens of companies are developing CAR-T and related engineered cell therapies for indications beyond cancer, including autoimmune diseases, neurological conditions, and solid tumors. The Novartis deaths will likely prompt heightened scrutiny of safety data across these programs and may slow the pace at which new CAR-T applications advance through clinical development. Investigators will be watching closely to see whether the fatal outcomes were specific to Novartis's particular CAR-T design and manufacturing process, or whether they reflect a more fundamental challenge with the approach itself when applied to autoimmune disease.
Citazioni salienti
Novartis stated it was pausing both its immunology-focused CAR-T programs and its neurological applications pending investigation into what went wrong— Novartis announcement
Vuoi la storia completa?
Leggi l'originale su Google News ↗
Health & Medicine